# Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

> **NCT00238446** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

## Interventions

- **DRUG:** EC-MPS

## Key facts

- **NCT ID:** NCT00238446
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238446, "Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00238446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*